Visceral leishmaniasis in Afghanistan

Leslie, Toby; Saleheen, Sarah; Sami, Mohammad; Mayan, Ismail; Mahboob, Najibullah; Fiekert, Kathy; Lenglet, Annick; Ord, Rosalynn; Reithinger, Richard
August 2006
CMAJ: Canadian Medical Association Journal;8/1/2006, Vol. 175 Issue 3, p245
Academic Journal
Presents information on visceral leishmaniasis in Afghanistan after the fall of the Taliban in 2002. Epidemiology; Information on various clinical management, such as pentavalent antimony therapy and therapeutic approaches that include miltefosine; Strategies to prevent and control visceral leishmaniasis.


Related Articles

  • Treatment of American Cutaneous Leishmaniasis with Miltefosine, an Oral Agent. Soto, J.; Toledo, J.; Gutierrez, P.; Nicholls, R. S.; Padilla, J.; Engel, J.; Fischer, C.; Voss, A.; Berman, J. // Clinical Infectious Diseases;10/1/2001, Vol. 33 Issue 7, pe57 

    There is no recognized oral treatment for American cutaneous leishmaniasis. A rising-dose, open-label phase I/II trial of the oral agent miltefosine against Colombian cutaneous leishmaniasis was conducted. Seventy-two male Colombian soldiers (mean weight, 67 kg) received miltefosine at 50--100...

  • Spatial and temporal variation and hotspot detection of kala-azar disease in Vaishali district (Bihar), India. Bhunia, Gouri Sankar; Kesari, Shreekant; Chatterjee, Nandini; Kumar, Vijay; Das, Pradeep // BMC Infectious Diseases;2013, Vol. 13 Issue 1, p1 

    Background: An improved understanding in transmission variation of kala-azar is fundamental to conduct surveillance and implementing disease prevention strategies. This study investigated the spatio-temporal patterns and hotspot detection for reporting kala-azar cases in Vaishali district based...

  • Infectious disease: Combating visceral leishmaniasis. Harrison, Charlotte // Nature Reviews Drug Discovery;Nov2013, Vol. 12 Issue 11, p828 

    The article discusses a research on the treatment of visceral leishmaniasis which references the study "Vaccination with Leishmania hemoglobin receptor-encoding DNA protects against visceral leishmanias," by R. Guha and colleagues in the 2013 issue of "Science Translational Medicine"

  • Kala-azar epidemic in Varanasi district, India. Kumar, R.; Kumar, P. // Bulletin of the World Health Organization;1999, Vol. 77 Issue 5, p371 

    Attempts to discover the epidemiological characteristics of the kala-azar outbreak in Varanasi district, India. History of fever and hepatosplenomegaly in all the cases; High disease prevalence among adults.

  • Visceral Leishmaniasis in the Indian Subcontinent: Modelling Epidemiology and Control. Stauch, Anette; Sarkar, Ram Rup; Picado, Albert; Ostyn, Bart; Sundar, Shyam; Rijal, Suman; Boelaert, Marleen; Dujardin, Jean-Claude; Duerr, Hans-Peter // PLoS Neglected Tropical Diseases;Nov2011, Vol. 5 Issue 11, p1 

    Background: In the Indian subcontinent, about 200 million people are at risk of developing visceral leishmaniasis (VL). In 2005, the governments of India, Nepal and Bangladesh started the first regional VL elimination program with the aim to reduce the annual incidence to less than 1 per 10,000...

  • Abstracts. Smith, Jeanette M. // JAMA: Journal of the American Medical Association;8/9/95, Vol. 274 Issue 6, p444q 

    Presents an abstract of the article `Endemic Kala-azar in Eastern Sudan: Post-Kala-azar Dermal Leishmaniasis,' by E.E. Ziglstra et al.

  • Investments in Research and Surveillance Are Needed to Go Beyond Elimination and Stop Transmission of Leishmania in the Indian Subcontinent. Olliaro, Piero L.; Shamsuzzaman, Tushar A. K. M.; Marasini, Baburam; Dhariwal, A. C.; Be-Nazir, Ahmed; Mondal, Dinesh; Banjara, Megha Raj; Das, Pradeep; Sundar, Shyam; Rijal, Suman; Arana, Byron; Alvar, Jorge; Argaw, Daniel; Peeling, Rosanna W.; Kroeger, Axel; Matlashewski, Greg // PLoS Neglected Tropical Diseases;1/26/2017, Vol. 11 Issue 1, p1 

    The article offers information on the Kala-azar Elimination Programme focusing to eliminate visceral leishmaniasis as a public health problem. It mentions improved treatments for visceral leishmaniasis offered through liposomal amphotericin B, paromomycin, and miltefosine. It also mentions that...

  • New therapy for visceral leishmaniasis.  // Weekly Epidemiological Record;6/21/2002, Vol. 77 Issue 25, p210 

    Reports on the use of miltefosine, manufactured by German pharmaceutical company Zentaris, as a chemotherapeutic agent for oral administration against the parasitic disease leishmaniasis. Transmission of leishmaniasis through the bite of the sandfly; Clinical trials conforming to international...

  • Control of visceral leishmaniasis in Brazil:recommendations from Brasileish. Ribeiro, Vitor Márcio; da Silva, Sydnei Magno; Menz, Ingrid; Tabanez, Paulo; Santos Nogueira, Fábio dos; Werkhaüser, Manfredo; da Fonseca, André Luis S.; Dantas-Torres, Filipe // Parasites & Vectors;2013, Vol. 6 Issue 1, p1 

    On 26 October 2012, veterinary medicine clinicians and researchers, members of Brasileish - Study Group about Animal Leishmaniasis - met at the Regional Council of Veterinary Medicine of Minas Gerais, in the city Belo Horizonte, in order to discuss many aspects of the situation of canine...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics